THRV-1268

Thryv Therapeutics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	THRV-1268
Sponsor	Thryv Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2) (PHASE2, PHASE3)
Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants (PHASE1)
Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

THRV-1268 CI brief — competitive landscape report
THRV-1268 updates RSS · CI watch RSS
Thryv Therapeutics, Inc. portfolio CI